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-Lactam resistance in methicillin-resistant Staphylococcus aureus (MRSA) is mediated by the expression of an alternative peni-
cillin-binding protein 2a (PBP2a) (encoded bymecA) with a low affinity for-lactam antibiotics. Recently, a novel variant of
mecA, known asmecC, was identified inMRSA isolates from both humans and animals. In this study, we demonstrate thatmecC-
encoded PBP2c does not mediate resistance to penicillin. Rather, broad-spectrum -lactam resistance inMRSA strains carrying
mecC (mecC-MRSA strains) is mediated by a combination of both PBP2c and the distinct -lactamase encoded by the blaZ gene
of strain LGA251 (blaZLGA251), which is part ofmecC-encoding staphylococcal cassette chromosomemec (SCCmec) type XI. We
further demonstrate thatmecC-MRSA strains are susceptible to the combination of penicillin and the -lactam inhibitor clavu-
lanic acid in vitro and that the same combination is effective in vivo for the treatment of experimentalmecC-MRSA infection in
waxmoth larvae. Thus, we demonstrate how the distinct biological differences betweenmecA- andmecC-encoded PBP2a and
PBP2c have the potential to be exploited as a novel approach for the treatment ofmecC-MRSA infections.
Antimicrobial resistance is a global health problem of particu-lar importance, which has led to an urgent need for new an-
timicrobial drug development. An alternative approach to this
problem is to resensitize resistant bacteria to existing antibiotics
by using novel inhibitors or synergistic combinations of existing
drugs that overcome themechanism(s) of resistance (1). The clas-
sical example of this is combinations of -lactamase inhibitors
such as clavulanic acid or sulbactams and a -lactam antibiotic.
Following the introduction of each generation of -lactam, resis-
tance rapidly emerged. In the case of Staphylococcus aureus, peni-
cillin resistance mediated by a blaZ-encoded -lactamase (peni-
cillinase)was followed by the emergence ofmethicillin-resistant S.
aureus (MRSA) shortly after the introduction of methicillin (a
-lactamase-resistant -lactam) in 1961 (2, 3).
Resistance to -lactam antibiotics in MRSA is mediated pri-
marily by the acquisition of an alternative penicillin-binding pro-
tein 2 (PBP2a) encoded by the mecA gene, which is carried on a
mobile element known as staphylococcal cassette chromosome
mec (SCCmec) (4). In 2011, a new type of MRSA isolate with a
divergentmecA homologue known asmecCwas described, which,
like some other types of MRSA, is associated with livestock (5, 6).
It has been demonstrated thatmecCmediates resistance to cefoxi-
tin and oxacillin in a range of strain backgrounds and that mecC
expression is inducible with oxacillin (7). mecC-encoded PBP2a
(PBP2c) shares only 63% amino acid identity withmecA-encoded
PBP2a (PBP2a). The difference in amino acid identity is reflected
in the distinct biochemical properties of PBP2c, whereby it shows
a greater affinity for oxacillin than for cefoxitin and is less stable at
37°C (8). Furthermore, unlike PBP2a, PBP2c does not require the
transglycosylase (TGase) activity of native PBP2 for high-level re-
sistance, suggesting that it may preferentially cooperate with an
as-yet-unidentified monofunctional TGase (8).
Here we report that the biological differences between PBP2a
and PBP2c extend to the unexpected finding that PBP2c does not
mediate resistance to penicillin and that expression of the strain
LGA251 -lactamase gene (blaZLGA251) located adjacent to mecC
on the SCCmec type XI element is required for broad-spectrum
resistance to -lactams. We demonstrate that this singular prop-
erty of PBP2c can be exploited therapeutically for the treatment of
infections caused by MRSA strains carrying mecC (mecC-MRSA
strains).
MATERIALS AND METHODS
Media and culture conditions. Bacterial strains and plasmids used in this
study are described in Table S5 in the supplemental material. For routine
culture, Escherichia coli was grown in lysogeny broth (LB) or on L agar
(Oxoid, United Kingdom) at 37°C. S. aureus was grown on tryptone soy
agar (TSA), Columbia blood agar, or tryptone soy broth (TSB) (Oxoid,
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UnitedKingdom) at 28°C or 37°C, accordingly. E. coli and S. aureusmedia
were supplemented with 10g/ml chloramphenicol (Cm10) as appropriate.
Antimicrobial susceptibility testing. Antimicrobial susceptibility
testing was performed by using disc diffusion susceptibility testing ac-
cording to BSAC criteria (9). All antibiotic discs were purchased from
Oxoid (United Kingdom). For the clavulanic acid assay, 15 g/ml potas-
sium clavulanate (Sigma-Aldrich, United Kingdom) was added to Iso-
Sensitest agar (ISA) or Mueller-Hinton agar (MHA) (Oxoid, United
Kingdom), as appropriate. Test isolates were grown to a 0.5 McFarland
standard in Iso-Sensitest broth (Oxoid, United Kingdom) and diluted
1:10 in distilled water before spreading onto agar plates with or without
potassium clavulanate. After application of the antibiotic discs to Iso-
Sensitest agar or Mueller-Hinton agar with 2% NaCl, as appropriate, all
plates were incubated at 35°C for 20 h before inhibition zones were mea-
sured. Broth microdilution for MICs was performed according to BSAC
guidelines (10). The ranges for MIC determination were 0.015 to 128
g/ml for penicillin and 1 to 32 g/ml for cefoxitin. For mecC-blaZ-
complemented strains, Iso-Sensitest broth was supplemented with 200
ng/ml anhydrotetracycline (Atc) to induce the expression of mecC and
blaZ from pXB01, a modified tetracycline-inducible expression vector
derived from pRMC2.
Construction of S. aureus gene deletion mutants. Oligonucleotide
primer sequences are listed in Table S5 in the supplemental material. By
using primers de-blaF and de-blaR, inverse PCR was performed on
pRMC2 using Kod Hot Start DNA polymerase (Merck, United King-
dom), according to the manufacturer’s instructions, to simultaneously
remove the resistance gene bla and introduce aNotI restriction site at each
end of the PCR product. After NotI digestion and self-ligation, amodified
tetracycline-inducible expression vector was obtained and designated
pXB01. mecC and blaZ deletion mutants in mecC-MRSA strains were
generated by allelic exchange with the temperature-sensitive vector
pIMAY, as described previously (11). The upstream sequence (PCR prod-
uct AB) and downstream sequence (PCR product CD) of the S. aureus
gene to be deleted were PCR amplified with primer pairs A/B and C/D,
respectively, using KodHot Start DNA polymerase (Merck, United King-
dom). PCR products AB and CDweremixed in a single PCRmixture and
fused by splicing by overlap extension PCR (SOE PCR) using Kod Hot
Start DNA polymerase (Merck, United Kingdom) and primer pair A/D to
obtain the deletion construct AD. Product AD was digested with the re-
striction enzymesKpnI and SacI and ligated into pIMAYdigestedwith the
same enzymes. The resulting plasmids were designated pIMAYmecC
and pIMAYblaZ. The plasmids were transformed into E. coli DC10B (a
dcm deletionmutant of DH10B, allowing the plasmid to be directly trans-
ferred into S. aureus strains [11]). Plasmid DNA extracted from DC10B
was then electroporated into recipient strains to create knockoutmutants.
mecC-blaZ double-deletionmutants were generated by deleting blaZ gene
frommecC deletion mutants using plasmid pIMAYmecCblaZ.
Complementation of mutant strains. For complement expression of
mecC and blaZ, the genes were cloned into expression plasmid pXB01, a
derivate of tetracycline-inducible expression vector pRMC2 with the bla
gene deleted (12). Both genes, including their ribosome-binding sites,
were amplified from LGA251 genome DNA with primer pairs mecC-F-
KpnI/mecC-R-SacI and blaZ-F-KpnI/blaZ-R-SacI. PCRproducts were di-
gested with KpnI and SacI and ligated with the pXB01 vector cleaved with
the same enzymes, generating plasmids pXB01-mecC and pXB01-blaZ.
The plasmidswere transformed intoE. coliDC10B, and plasmidDNAwas
then extracted and electroporated into mutant strains for complementa-
tionwith expression inducedwith 200 ng/ml anhydrotetracycline (Sigma-
Aldrich, United Kingdom).
Wax moth larva (Galleria mellonella) infection and treatment as-
say. The wax moth larva assay was based on a method described previ-
ously by Desbois and Coote (13). Galleria mellonella larvae were pur-
chased in bulk from a commercial supplier (Livefood Ltd., United
Kingdom). Larvaewere stored at 4°C upon arrival and kept at 37°C during
the course of the assay. mecC-MRSA strains LGA251, 02.5099.D, and
71277 were selected for evaluation of antimicrobial activities of penicillin
and clavulanic acid in combination. Single bacterial colonies were picked
for inoculation into 5ml of TSB, and cultures were grown overnight (16
h) at 37°C and at 200 rpm. Cultures were then diluted 1:100 into 5 ml of
fresh TSB and grown for a further 4 h at 37°C and at 200 rpm. Cultures
were then centrifuged at 2,500  g for 10 min, and pellets were resus-
pended in sterile phosphate-buffered saline (PBS) to an optical density at
595 nm (OD595) of 0.2, giving1.3 10
6 CFU (range, 1.1 106 to 1.4
106 CFU) in 10 l. For each strain, six groups ofG. mellonella larvae (n
10 in each group) were injected with 10-l aliquots of the resuspended
culture between two posterior thoracic segments by using a Tridak Step-
per pipette dispenser (Dymax, United Kingdom). Groups ofG.mellonella
larvae were treated by injection with 50 mg/kg of body weight vancomy-
cin, 40 mg/kg cefoxitin, 20 mg/kg penicillin sodium salt, 20 mg/kg potas-
sium clavulanate, 20 mg/kg penicillin sodium salt combined with 20
mg/kg potassiumclavulanate, or PBS 2, 24, and 48 h after inoculation. The
treatments were given blind, and the treatment identities were not re-
vealed until the experiment was completed. Larvae were considered dead
when they did not respond to a touch to the head. The experiment was
performed twice, with almost identical results; results of one experiment
are presented below (see Fig. 5), and the results for the second experiment
are presented in Fig. S3 in the supplemental material.
In vitro selection of penicillin resistance. LGA251 and 02.5099.D
were serially passaged for 40 days with subinhibitory concentrations of
penicillin in the presence of 15g/ml clavulanic acid. Briefly, strains were
grown on Columbia blood agar, and four single colonies were used to
make a 0.5McFarland standard in Iso-Sensitest broth. This was diluted to
a final 1:200 dilution in 2 ml of Iso-Sensitest broth with a range of 2-fold
penicillin concentrations (0.03125 to 4 g/ml) and a fixed concentration
of 15g/ml clavulanic acid. After incubation for 24 h at 37°Cwith shaking
at 200 rpm, the culture with the highest antibiotic concentration showing
clear visible growth was adjusted back to a 0.5 McFarland standard, used
to inoculate a fresh set of tubes as described above, and incubated for
another 24 h. Once growth occurred at the 4-g/ml concentration of
penicillin, the increment was changed from 2-fold increases to 2-g/ml
increases. At selected time points, cultures were plated out, 2 to 3 resistant
colonies were picked, penicillin and cefoxitinMICs were determined, and
themecC gene was amplified by PCR using primers mecCf, mecCm, and
mecCr and sequenced (Source Bioscience Sequencing, Cambridge,
United Kingdom) (see Table S5 in the supplemental material). Strains
LGA251blaZ and 02.5099.DblaZwere also serially passaged for 40 days
with subinhibitory concentrations of penicillin in the samemanner but in
the absence of clavulanic acid.
Bioinformatics analysis. -Lactamase sequences of type A (GenBank
accessionnumberEVL36279), typeB (accessionnumberAGU62029.1), type
C (accession number WP_015056218), and type D (accession number
Q53699) were downloaded from the NCBI database. Alignments were
generated by using Muscle in Seaview (14, 15). For phylogeny, blaZ from
Macrococcus caseolyticus (accession number WP_041636568) was in-
cluded as an outgroup, and blaZ from Staphylococcus xylosus (accession
number CCM44120) was included for comparison (16). Maximum like-
lihood phylogenetic trees were constructed by using PhyML v3.0 in
Seaviewwith aWhelan andGoldman (WAG) substitutionmodel and 100
bootstrap replicates (17).
RESULTS
PBP2cdoesnotmediate resistance topenicillin.Previouslywork
by Kim et al. identified that PBP2a encoded bymecC (PBP2c) had
a higher relative affinity for oxacillin than for cefoxitin, suggesting
that PBP2c has a higher affinity for penicillins than for cephalo-
sporins (8). The class E mec complex (mecI-mecR1-mecC-blaZ)
present in SCCmec type XI contains a blaZ gene (here blaZLGA251)
present downstream of themecC gene. blaZLGA251 is phylogeneti-
cally distinct from other previously reported blaZ genes in S. au-
reus (Fig. 1A), and mecC-MRSA strains with blaZLGA251 do not
-Lactam Resistance in mecC-MRSA Strains
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harbor any other blaZ genes (data not shown). Currently, there
are four types (types A toD) of staphylococcal-lactamases based
on differences of amino acids at positions 128 and 216 (18, 19). At
position 216, blaZLGA251 shares a serine with type A and D blaZ
genes (Fig. 1B), while at position 128, blaZLGA251 uniquely has a
leucine. Therefore, we propose that blaZLGA251 is a new staphylo-
coccal blaZ type, type E blaZ (Fig. 1).
As PBP2c confers low-level resistance to penicillins such as
oxacillin, and the SCCmec type XI mec complex included a novel
type of blaZ gene, we investigated the relative contribution of
mecC and blaZLGA251 to -lactam resistance. We generated gene
deletions ofmecC, blaZ, and bothmecC and blaZ in two different
mecC-MRSA strains: LGA251, a strain of multilocus sequence
type 425 (ST425) isolated from cattle in England, and 02.5099.D,
FIG 1 (A) Maximum likelihood tree generated from amino acid sequences showing relationships of staphylococcal -lactamases. Values above the branches
indicate bootstrap support. (B) Alignment of the amino acid sequences of representative type A to D -lactamases in comparison with the SCCmec type
XI-encoded type E (LGA251) -lactamase. Highlighted residues indicate amino acids at positions 128 and 216 used to type the -lactamase.
Ba et al.
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a ST1944 (CC130) isolate from human infection in Scotland (5).
Deletion of mecC in LGA251 (LGA251mecC) and in 02.5099.D
(02.5099.DmecC) caused a loss of resistance to cefoxitin, asmea-
sured by disc diffusion and MIC assays, while complementation
withmecC restored resistance, as previously reported (Fig. 2A; see
also Table S1 in the supplementalmaterial) (7).However, deletion
of mecC caused no reduction in penicillin resistance in either
LGA251 or 02.5099.D, demonstrating thatmecC did not mediate
resistance to penicillin in the background of either strain (Fig. 2B;
see also Table S1 in the supplemental material). In contrast, when
the blaZLGA251 gene was deleted, resistance to penicillin was abol-
ished in both strain backgrounds, and the penicillin MIC de-
creased from 8 to0.0075g/ml and from 32 to 0.0625g/ml in
LGA251 and 02.5099.D, respectively (Fig. 2B; see also Table S1 in
the supplemental material). Complementation of the mutants
with blaZ restored penicillin MICs to wild-type levels in both
backgrounds (Fig. 2B; see also Table S1 in the supplemental
material). These findings were confirmed by the creation of
mecC-blaZ double-deletion strains (LGA251mecCblaZ and
02.5099.DmecCblaZ), which were then individually com-
plemented with plasmid-borne copies of mecC and blaZ. In
each case, complementation with blaZ and not complementa-
tion with mecC restored resistance to penicillin (Fig. 2B; see
also Table S1 in the supplemental material).
mecC-MRSA strains are susceptible to the combination of
clavulanic acid and penicillin in vitro. As penicillin resistance in
mecC-MRSA strains is mediated by blaZLGA251 alone, we tested
whethermecC-MRSA strains were susceptible to the combination
of penicillin and clavulanic acid (a -lactamase inhibitor). We
included clavulanic acid at a clinically relevant concentration of 15
g/ml in bacteriological medium and carried out penicillin and
cefoxitin disc diffusion assays, according to BSAC criteria, against
a panel of 30 mecC-MRSA isolates (Fig. 3) (20, 21). This analysis
showed that clavulanic acid increased susceptibility to penicillin in
all strains tested (except for strain Sa09315, which was already
susceptible due to a frameshift in blaZ) andmore thandoubled the
mean zone of inhibition (10 versus 27 mm; resistance cutoff of 24
mm) (Fig. 3). Furthermore, clavulanic acid reduced the penicillin
MICs by a mean of 65-fold and restored breakpoint susceptibility
in 24 of 30 strains tested (Fig. 3A). In the remaining 6 strains, the
MICwas reduced to the breakpoint (breakpoint, 0.12g/ml) (Fig.
3A). In contrast, only minor reductions were seen for cefoxitin
combined with clavulanic acid (Fig. 3B). In view of the relative
instability of PBP2c at higher temperatures (the assays were per-
formed at 35°C), we confirmed the effect of clavulanic acid on
cefoxitin and penicillin at 25°C, 30°C, and 37°C. The results for
cefoxitin showed a clear increase in the zone of inhibition with
increasing temperature, as previously reported, with no major ef-
fect of clavulanic acid being seen at any temperature (8) (see Fig.
S1 in the supplemental material), while for penicillin, there was
only a minor effect with increasing temperature and similar zones
of inhibition in the presence and absence of clavulanic acid (see
Fig. S1 in the supplemental material). Together, these data dem-
onstrate that the effect of clavulanic acid was not due to the tem-
perature-sensitive activity of PBP2c at 35°C.
Role ofmecC and blaZ in resistance against a broad range of
-lactam antibiotics. We next tested the effect of clavulanic acid
on resistance against a broad range of-lactam antibiotics (8 pen-
icillins, 12 cephalosporins, 1 monobactam, and 3 carbapenems)
for the same panel of 30mecC-MRSA strains. The results showed
that clavulanic acid increased susceptibility to all penicillins tested
except for oxacillin (Fig. 3C; see also Table S2 in the supplemental
material). Oxacillin was tested onMueller-Hinton agar as recom-
mended by BSAC (9), EUCAST (34), and CLSI (35) guidelines
and also by using Iso-Sensitest agar, where there was a small de-
crease in the presence of clavulanic acid (mean, 20 versus 24mm),
which was less than that observed for other penicillins. The effect
of clavulanic acid was most pronounced for penicillin (mean, 11
versus 27 mm), amoxicillin (mean, 22 versus 34 mm), ampicillin
(mean, 24 versus 36mm), and temocillin (mean, 7 versus 17mm)
(Fig. 3; see also Table S2 in the supplemental material). Only
very small increases in susceptibility were seen in the presence
of clavulanic acid for the tested cephalosporins and carbapen-
ems, and no effect at all was seen for the one monobactam
tested (aztreonam) (Fig. 3; see also Table S2 in the supplemen-
tal material).
FIG 2 Effect of deletion ofmecC and blaZ in strains LGA251 and 02.5099.D on theMICs of cefoxitin (A) and penicillin (B). For each strain background (LGA251
and 02.5099.D), the first strain is the wild type, followed to the right by its various mutants and complemented mutants.	p denotes complementation with the
empty vector, where	pmecC indicates complementation with a vector-borne copy ofmecC and	pblaZ indicates complementation with a vector-borne copy
of blaZ.
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To further understand the basis for the effect of clavulanic acid,
we next tested the mecC and blaZ deletion mutant strains against
the same range of -lactams in disc diffusions assays, alone and in
the presence of 15 g/ml clavulanic acid (see Table S1 in the sup-
plemental material). The results showed that the effect of clavula-
nic acid on penicillin resistance was negated in both strains
LGA251blaZ and 02.5099.DblaZ, indicating that, as would be
expected, the zone increases mediated by clavulanic acid were de-
pendent on the blaZLGA251-encoded -lactamase (see Table S1 in
the supplemental material). Interestingly, the presence of clavu-
lanic acid alone in the medium prevented the growth of both
mecC strains. Furthermore, complementation with mecC on a
plasmid failed to reverse this, nor was this effect seen in either of
the blaZ strains (LGA251blaZ and 02.5099.DblaZ), demon-
strating that it was not a by-product of the mutant construction
process per se but most likely due to the specific loss of chromo-
somalmecC (see Table S1 in the supplemental material).
Selection of penicillin resistance in mecC-MRSA isolates.
Next, we sought to elucidate the molecular basis for why PBP2c
was unable to mediate resistance to penicillin. We first attempted
to identifymecCmutations that conferred resistance to penicillin
by screening a collection of whole-genome-sequenced mecC-
MRSA isolates (data not shown) to identify naturally occurring
amino acid substitutions. We identified 10 different amino acid
substitutions present in PBP2c and tested representative isolates
by penicillin disc diffusion with clavulanic acid to see if there was
FIG 3 Effect of clavulanic acid onmecC-MRSA strains. (A and B) Penicillin MICs (A) and cefoxitin MICs (B) for individual isolates in the presence (red) and
absence (black) of clavulanic acid. (C) Mean results for a panel of 30 mecC-MRSA strains tested against a range of -lactam antibiotics, as measured by disc
diffusion assays, in the presence and absence of clavulanic acid. The error bars represent standard errors. Two- and three-letter codes and concentrations of discs
are shown below each class of -lactam antibiotic. Note that results are shown for oxacillin on two different media: Iso-Sensitest agar and Mueller-Hinton agar
with 2% NaCl at 30°C (BSAC-recommended media [9]). Resistance breakpoints for penicillin, oxacillin, and cefoxitin are 24 mm, 14 mm, and 21 mm,
respectively. The BSACMIC breakpoints for penicillin (Pen) and cefoxitin (Fox) are 0.12 and 4 g/ml, respectively. Clavulanic acid was included in the media
at 15 g/ml.
Ba et al.
7400 aac.asm.org December 2015 Volume 59 Number 12Antimicrobial Agents and Chemotherapy
 o
n
 D
ecem
ber 8, 2015 by UNIVERSITY O
F HULL
http://aac.asm
.org/
D
ow
nloaded from
 
any effect on penicillin susceptibility (Table 1). None of the iso-
lates tested showed any resistance to the combination of penicillin
and clavulanic acid.We next sought to select mutants in vitrowith
PBP2c mutations conferring penicillin resistance. We grew two
wild-type mecC-MRSA strains, LGA251 and 02.5099.D, with
gradually increasing concentrations of penicillin supplemented
with clavulanic acid at 15g/ml for 40 days (Fig. 4). We also grew
the corresponding isogenic blaZ mutants (LGA251blaZ and
02.5099.DblaZ) in penicillin alone (Fig. 4). At a number of
points in the experiment, isolates were plated as single colonies, 2
to 3 individual colonies were tested for penicillin and cefoxitin
MICs, and mecC was sequenced to identify potential mutati-
ons mediating penicillin resistance (Fig. 4). MIC testing of
LGA251blaZ from day 9 and of 02.5099.DblaZ from day 13
showed that as well as becoming penicillin resistant, these strains
showed substantially increased resistance to cefoxitin (8 versus
128 g/ml), suggesting that the change seen was a general in-
crease in -lactam resistance and not specific to penicillin (see
Table S3 in the supplemental material). Only colonies from wild-
type strain 02.5099D grown in penicillin and clavulanic acid at day
40 (02.5099-D40-A) revealed the presence of a G-to-A mutation
at position 1636 in mecC causing a Val546Ile substitution in the
transpeptidase domain in PBP2c. None of the other strains
screened had any mecC mutations, suggesting that resistance was
due to mutations elsewhere in the chromosome or an upregula-
tion of genes involved in resistance. Disc diffusion testing of two
individual colonies (02.5099-D40-A-C1 and 02.5099-D40-A-C2)
with the Val546Ile substitution showed that resistance had in-
creased to all -lactam antibiotics except for aztreonam, to which
the strains were already completely resistant, and to ceftaroline,
the new anti-MRSA cephalosporin (see Table S4 in the supp-
lemental material). We cloned the mutated mecC gene
(mecCVal546Ile) from 02.5099-D40-A-C1 and 02.5099-D40-A-C2
into RN4220 and into blaZ-mecC-null strains LGA251blaZmecC
and 02.5099.DblaZmecC and tested resistance to penicillin and
cefoxitin using disc diffusion. We found that the strains with
mecCVal546IIe were equally as susceptible to penicillin as wild-type
mecC, demonstrating that the Val546Ile substitution alone was
not capable of mediating resistance (see Fig. S2A and Table S4 in
the supplemental material). Interestingly, however, when we
tested the mecCVal546Ile strains for cefoxitin resistance, we found
that the strains were not resistant to cefoxitin, as measured by disc
diffusion, and had anMIC of 2g/ml, in comparison to 16g/ml
for strains expressing wild-typemecC (see Fig. S2B andTable S4 in
TABLE 1 Locations of amino acid substitutions in PBP2c in wild-type strains and location of the substitution found in strain 02.5099-D40-Aa
Representative strain No. of isolates tested
Amino acid substitution at position:
63 130 145 173 185 269 346 349 466 482 546
LGA251 1 N V K N R Y A P R D V
0820 A 1 S
52902 2 N
ST20120827 1 I
77964 9 K
Sa13307 4 K
M4A 1 A
71957 14 H
m-40-71 1 L
1198/2006 1 I
51618 1 C
02.5099-D40-A 1 I
a Residues likely to be in the transpeptidase domain (residues 324 to 665) based on alignment with PBP2a are shown in boldface type.
FIG 4 In vitro selection of penicillin resistance. Graphs show changes in subinhibitory concentrations for mutant mecC-MRSA strains LGA251blaZ and
02.5099.DblaZ (A) orwild-typemecC-MRSA strains LGA251 and 02.5099.D (B), during the course of in vitropenicillin resistance selection (A) or penicillin and
clavulanic acid selection (B), grown in continuous culture with Iso-Sensitest broth at 37°C. Arrows indicate time points selected formecC gene sequencing.
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the supplemental material). Further disc diffusion testing against
the full panel of-lactams revealed that the Val546Ile substitution
affected resistance to cefoxitin only (see Table S4 in the supple-
mental material). This demonstrates the importance of valine at
position 546 for specifically mediating cefoxitin resistance in
PBP2c.
The combination of clavulanic acid andpenicillin is effective
in vivo for treatment of mecC-MRSA infections. Finally, we
sought to determine if the effect of penicillin and clavulanic acid
seen in vitro could translate to therapeutic treatment of S. aureus
infection in vivo. We used the wax moth larva model of infection
with 3 differentmecC-MRSA strains belonging to different multi-
locus sequence types: LGA251 (ST425), 02.5099.D (ST1944), and
71277 (ST130) (13). We compared the effect of penicillin-clavu-
lanic acid (2:1) with penicillin, clavulanic acid, cefoxitin, and PBS
against the “gold-standard” treatment of vancomycin (Fig. 5). For
both LGA251 and 02.5099.D, 10% of larvae treated with PBS or
clavulanic acid survived to 120 h, while for 71277, larvae were all
dead by 48 and 68 h, respectively (Fig. 5). Treatment with penicil-
lin alone led to amodest improvement, with survival rates at 120 h
of 20% for LGA251, 30% for 02.5099.D, and 20% for 71277 (Fig.
5). Despite the presence of PBP2c, cefoxitin performed moder-
ately better than penicillin, with survival rates at 120 h of up to
40% for LGA251 and 71277 and up to 50% for 02.5099.D. In
contrast, survival rates at 120 h for penicillin and clavulanic acid
were 90% for LGA251, 65% for 71277, and 70% for 02.5099.D
(Fig. 5), while the gold-standard treatment of vancomycin had
survival rates at 120 h of 90% for LGA251 and 80% for 02.5099.D
and 71277 (Fig. 5). Statistical analysis showed that there was no
significant difference between treatment with the combination of
penicillin and clavulanic acid and treatment with vancomycin
(P 0.970 for LGA251, P 0.259 for 02.5099.D, and P 0.370
for 71277 [as determined by a log rank {Mantel-Cox} test]). Re-
peat experiments showed broadly identical results (see Fig. S3 in
the supplemental material).
DISCUSSION
Antibiotic resistance is a major international problem, with few
new antibiotics likely to be available in the immediate future.
Novel methods to combat antibiotic resistance are therefore re-
quired, including repurposing older antibiotics. Here we present
evidence of one such case. We show that the newly described
mecC-encoded PBP2c does not mediate resistance to penicillin
and that the adjacent type E blaZ gene is required for resistance to
penicillin. Our data suggest that this biological difference can be
exploited for treatment by combining penicillin and clavulanic
acid, a -lactam inhibitor, to block the action of the blaZLGA251-
encoded -lactamase. Importantly, we show that our in vitro data
translate to successful treatment of experimental infections in vivo
in a nonvertebrate model. The combination of penicillin and cla-
vulanic acid was as effective as vancomycin in reducing the mor-
tality of wax moth larvae infected with three different mecC-
MRSA strains. We also observed in vitro activity of clavulanic acid
in combination with amoxicillin, a combination that is already
commercially available (Augmentin), suggesting that drugs al-
ready in clinical use might be successful in treating mecC-MRSA
infections. Additionally, variable resistance to different cephalo-
sporins was reported previously formecC-MRSA isolates, suggest-
ing that certain cephalosporins might also be also be used for
treatment (22). Our data for 30 mecC-MRSA isolates found uni-
form zones of inhibition (Fig. 3C) for all the cephalosporins
tested, including susceptibility to ceftaroline (the new anti-MRSA
cephalosporin). However, given the reliance on cefoxitin-oxacil-
lin testing for MRSA detection, there is a lack of clinical break-
points for most cephalosporins; therefore, it is not clear if these
zones of inhibition would translate into clinical efficacy, and fur-
ther work is required to address this question.
FIG 5 Experimental treatment of Galleria mellonella larvae infected bymecC-
MRSA strains LGA251 (A), 02.5099.D (B), and 71277.10 (C). Ten larvae in
each group were experimentally infected and then treated at 2, 24, and 48 h
with vancomycin (50 mg/kg; 6.73 10
9 mol), penicillin (20 mg/kg; 1.12
10
8 mol), clavulanic acid (20 mg/kg; 1.69 10
8 mol), penicillin-clavulanic
acid, cefoxitin (40 mg/kg; 1.78  10
8 mol), and PBS alone. Shown are data
from a single experiment.
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These findings suggest that penicillin can readily bind to PBP2c
to prevent cell wall biosynthesis, a notion supported by data re-
ported previously by Kim et al., which showed a higher binding
affinity of PBP2c for penicillins than for cephalosporins, in com-
parison to PBP2a (8). This is consistent with our finding that
clavulanic acid was effective at conferring increased susceptibility
to all the tested penicillins (except oxacillin) but had no effect
against cephalosporins. It remains to be seen if this property is
conserved among the variants of mecC identified in different co-
agulase-negative staphylococci (16, 23–25).
Biologically, the finding that PBP2c has evolved so as not to
mediate resistance to penicillin is of interest. The linkage of both
mecC and blaZLGA251 on a single genetic element might have en-
abled PBP2c to evolve properties distinct from those of PBP2a,
without the constraint of having to mediate resistance to penicil-
lin. This might suggest that the selective pressure tomediate resis-
tance to cephalosporins or an as-yet-unidentified-lactam(s) un-
der specific conditions (temperature, pH, and ion concentration,
etc.) selected PBP2c to be unable to mediate resistance to penicil-
lin. Indeed, a previous demonstration that PBP2c is unstable at
37°C suggests that selection pressures might have selected for
function at lower temperatures (8). Equally, it is known that there
are specific fitness costs associated with the expression of PBP2a,
including a loss of toxicity and altered biofilm formation, and that
high-level -lactam resistance requires epistatic mutations (26–
29). The distinct advantage of PBP2c in comparison to PBP2a or
the selective pressures that have driven this remain to be deter-
mined.
mecC-MRSA strains are commonly isolated from cattle (30),
and it is possible that the routine use of both first- and third-
generation cephalosporins for the treatment and prevention of
mastitis may have provided the selective pressure that has driven
the emergence of mecC-MRSA strains in dairy cows (31). Future
studies should be targeted to investigate this question to provide
insight for improvements in antibiotic stewardship in veterinary
medicine.
We have also identified the first mutation associated with a
specific loss of cefoxitin resistance in PBP2c. Comparison of the
PBP2c and PBP2a structures suggests that this substitution might
affect lobe-lobe positioning; also, V546 is adjacent to a beta strand
“cascade” that likely packs differently in PBP2c/PBP2a protein
cores; i.e., V546(c)/L549(a) sits adjacent to I354(c)/L357(a),
which could propagate all the way up tomotif III (KSG) andmotif
I (SXXK) at the active site (see Fig. S4 in the supplemental mate-
rial) (32, 33). Further structural insights into the difference be-
tween the two proteins are required to shed further light on our
understanding of the distinct biological properties of PBP2a and
PBP2c.
In conclusion, our findings further highlight how the limited
functional sequence space can be exploited for antibiotic drug
design and synergistic therapy. This is particularly important
given the increasing challenges posed bymultidrug resistance and
offers a paradigm for tackling an emerging, resistant bacterial
pathogen with an old antibiotic.
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